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Aims Although cardiac resynchronization therapy (CRT) is effective in patients with systolic heart failure (HF) and a wide
QRS interval, a substantial proportion of patients remain non-responsive. The SonR contractility sensor embedded
in the right atrial lead enables individualized automatic optimization of the atrioventricular (AV) and interventricular
(VV) timings. The RESPOND-CRT study investigated the safety and efficacy of the contractility sensor system in
HF patients undergoing CRT.
...................................................................................................................................................................................................
Methods
and results
RESPOND-CRT was a prospective, randomized, double-blinded, multicentre, non-inferiority trial. Patients were
randomized (2:1, respectively) to receive weekly, automatic CRT optimization with SonR vs. an Echo-guided opti-
mization of AV and VV timings. The primary efficacy endpoint was the rate of clinical responders (patients alive,
without adjudicated HF-related events, with improvement in New York Heart Association class or quality of life),
at 12 months. The study randomized 998 patients. Responder rates were 75.0% in the SonR arm and 70.4% in the
Echo arm (mean difference, 4.6%; 95% CI, 1.4% to 10.6%; P< 0.001 for non-inferiority margin 10.0%) (Table 2).
At an overall mean follow-up of 5486 190 days SonR was associated with a 35% risk reduction in HF hospitaliza-
tion (hazard ratio, 0.65; 95% CI, 0.46–0.92; log-rank P¼ 0.01).
...................................................................................................................................................................................................
Conclusion Automatic AV and VV optimization using the contractility sensor was safe and as effective as Echo-guided AV and
VV optimization in increasing response to CRT.
...................................................................................................................................................................................................
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Introduction
Cardiac resynchronization therapy (CRT) is an effective and estab-
lished therapy for patients with medically refractory heart failure
(HF), left ventricular (LV) systolic dysfunction (ejection fraction
35%), and a wide QRS complex.1 CRT improves the functional class
and quality of life (QoL) and remodels the heart favourably, while
reducing the rates of HF hospitalization and overall mortality in this
large subgroup of HF patients.2,3 Despite these salutary effects of
CRT, a significant minority (30%) of patients remain non-responsive
to this therapeutic modality.4 Amongst several factors that could ad-
versely affect response, suboptimal optimization of the atrioventricu-
lar (AV) and interventricular (VV) timings of the CRT device
constitute the commonest and most supposed correctable variable.5
Several studies have demonstrated the acute haemodynamic benefits
of Echo-guided AV and VV timings optimization.6
Of note, Echo-guided optimization remains a logistically challeng-
ing and a resource-intensive process, with the programming param-
eters measured at rest and in the supine position.7 There is an unmet
need for an individualized, device-based strategy that can automatic-
ally optimize the AV and VV electrical timings, on a repetitive basis
during rest and exercise. Novel technology using the SonR contractil-
ity sensor enables this automatic optimization.8 Several studies have
shown that cardiac contraction generates mechanical vibrations that
propagate through the entire heart. The sensor records these as
SonR signals that correlate strongly with LV dP/dtmax, a measure of
cardiac contractility.9,10
A pilot study (CLEAR) assessing this contractility sensor within the
right ventricular lead of a CRT-pacemaker implant showed a trend to
improvement in clinical outcomes.8 Built off this preliminary data, a
new dedicated right atrial lead with an embedded sealed sensor was
evaluated in this large, prospective, double-blind, randomized non-
inferiority clinical trial in patients eligible for implantation of a CRT-D
device.11 The RESPOND-CRT study investigated the safety and effi-
cacy of the contractility sensor system in HF patients undergoing CRT.
Methods
Study design and oversight
The Clinical Trial of the SonRtip lead and automatic AV-VV optimiza-
tion (RESPOND-CRT) was a prospective, multicentre, randomized,
double-blind, non-inferiority trial. The study was designed by a
Steering Committee and the sponsor (LivaNova), approved by the
Food and Drugs Administration (FDA) as an Investigational Device
Exemption (IDE) study, and has been described previously.11 An in-
dependent Clinical Events Committee reviewed all relevant events
and an independent Data Safety Monitoring Board regularly reviewed
the safety data (see Supplementary material online).
The last author (J.P.S.) wrote the first draft of the manuscript,
which was revised and approved by all co-authors. The authors ac-
cept full responsibility for the accuracy and completeness of the data
and all analyses, and for the fidelity of this report of the trial protocol.
Study population and intervention
The trial enrolled patients with clinical indications for implantation of
a de novo CRT defibrillator (with or without a pre-existing
implantable cardioverter-defibrillator or pacemaker), according to
current guidelines.12,13 The study was approved by local ethics com-
mittees (investigational review boards and health authorities).
Patients provided written informed consent.
The main inclusion criteria were New York Heart Association
functional class III or ambulatory IV, LV ejection fraction 35%, sinus
rhythm, and QRS complex 120 ms of left bundle-branch block
(LBBB) morphology, or QRS complex> 150 ms in non-LBBB.
The complete list of study criteria is provided in the Supplementary
material online.
Patients underwent full echocardiographic evaluation, and a global
clinical status (NYHA) assessment and quality-of-life (QoL) question-
naire using the Kansas City Cardiomyopathy Questionnaire14.
Patients were then implanted with a CRT-defibrillator device
(PARADYM RF SonR 9770, LivaNova), connected to a straight, ac-
tive fixation bipolar atrial pacing lead (SonRtip, LivaNova). Within 14
days of a successful implant, patients were randomized (2:1, respect-
ively) to weekly automatic AV and VV delay optimization with SonR
or to Echo-guided optimization (Echo), using a mandatory standar-
dized protocol (AV timing was optimized using the iterative method,
and the VV timing was set up through the aortic velocity time integral
measurement). Further details on the optimization procedures are
provided in the Supplementary material online. Clinical status evalu-
ation and QoL questionnaire administration were performed 3, 6,
and 12 months postimplant by clinicians blinded to the randomization
assignment. A second echocardiogram was performed at 12 months.
Measurements were reviewed by a centralized independent core la-
boratory (see Supplementary material online).
Device under investigation
During cardiac contraction the myocardium generates mechanical vi-
brations that propagate throughout the heart. The SonR sensor re-
cords an endocardial acceleration signal corresponding to these
vibrations. The highest amplitude of the signal occurs during the iso-
volumetric contraction phase of the cardiac cycle and corresponds
to the cardiac contractility.15 The correlation between the amplitude
of the recorded signal and LV dP/dtmax, as a surrogate of the contract-
ile function of the heart, has been demonstrated.16 The signal ampli-
tude corresponds to the first heart sound and is an index of systolic
function.10 The sensor is embedded in the tip of a bipolar, active fix-
ation, right atrial pacing lead (SonRtip) (Figure 1). The system com-
posed of the lead and the CRT-D device automatically adjusts the AV
and VV delays, on a weekly basis, at rest and exercise.17
Concordance between echocardiographic methods and this device-
based method has been demonstrated.18
Study outcomes
The primary efficacy endpoint was the rate of clinical responders
(comprising a nested composite of patients alive, without adjudicated
HF-related events, with improvement in New York Heart Association
(NYHA) class improvement of 1 level or QoL improvement of at
least 5 points, at 12 months). NYHA and QoL were assessed at 3, 6
and 12 months. Primary safety endpoints were freedom from acute
(0–3 months) and chronic (3–12 months) atrial lead-related complica-
tions. All events (including HF-related events and lead-related compli-
cations, and other serious adverse events) were adjudicated by the
blinded Clinical Events Committee. Secondary endpoints included the
Results of the RESPOND-CRT study 731
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rate of clinically worsened patients and the composite of all-cause
mortality or HF hospitalization. Pre-specified ancillary analysis was
conducted on all data available at the time of database lock on all-
cause mortality or HF hospitalization and its component, HF hospital-
ization. Left ventricular ejection fraction and LV end-systolic volumes
were ancillary endpoints. Full details on endpoint definition are pro-
vided in the Supplementary material online.
Statistical analysis
The sample size determination is detailed in the Supplementary
material online.
For the analysis of the primary efficacy endpoint, the status of the
patient towards hard endpoints (mortality or HF-related events) had
to be known at 12 months. For NYHA and QoL, 3- or 6-month eval-
uations would be used if the 12-month assessment was not available
(Lost Observation Carried Forward method).
Non-inferiority on primary CRT efficacy endpoint was tested using
a one-sided Z-test of two binomial proportions with an alpha level of
0.025, and a10.0% pre-defined absolute non-inferiority margin.8
All efficacy analyses were conducted on the modified intention-to-
treat (mITT) population which included all randomized patients suc-
cessfully implanted with the full entire system with an evaluable pri-
mary efficacy endpoint data.
A method of worst case data imputation was used to address miss-
ing values. The patients lost to follow-up or with missing data at 12
months were imputed as non-responders.
The primary lead safety endpoints: rate of freedom from acute and
rate of freedom from chronic lead complications were compared
with 91%19 and 94%20 pre-specified values, respectively, using a one-
sided exact test of one binomial proportion at an alpha level of 0.025.
The safety analyses were performed on the safety population
which included all patients successfully implanted with SonRtip lead
and patients with SonRtip lead fracture, insulation breach or perfor-
ation occurring during the implant procedure, regardless successful
implantation.
If all statistical tests were passed, the secondary CRT efficacy
endpoints, rate of clinically worsened patients, and the rate of com-
posite of all-cause mortality or HF hospitalization were tested using a
10.0% absolute non-inferiority margin.
The pre-specified long-term ancillary time-to-event analyses were
conducted using Kaplan–Meier statistics on all follow-up data avail-
able at the time of the 12 month database lock. The log-rank test and
hazard ratios with 95% confidence intervals (CIs) were estimated
from the Cox proportional hazard model.
Echocardiographic parameters were assessed on patients with data
at implant and at 1 year follow-up. Mean intra-patient changes from
baseline to 12 months in LV ejection fraction and LV end-systolic vol-
ume were tested in each group using a paired t-test or Wilcoxon test.
Mean changes were compared between groups using one-sided non-
inferiority test, with an alpha level of 0.025 and a pre-defined absolute
non-inferiority margin of 2.5% in LV ejection fraction and 15 mL in
LV end-systolic volume, respectively. A logistic regression model was
used to estimate odds ratios with 95% CIs in pre-defined subgroup
analyses. For each of the pre-specified subgroups, interactions between
the subgroup and the randomly assigned group were tested without
adjusting for multiple comparisons. Categorical variables are reported
as frequencies and percentages, and continuous variables as
mean6 standard deviation. P-values for non-inferiority are one-sided
in nature, whereas all other tests are two-sided. Analyses were per-
formed using the SAS software version 9.4.
Results
Patients
A total of 1039 patients were assessed for eligibility from 125 sites in
12 countries in Europe, Australia, and North America, from 13
January 2012 through 29 October 2014. Of these patients, 670 were
randomly assigned to SonR and 328 to Echo (Figure 2). One patient
was lost to follow-up. Nineteen patients were excluded from the
analysis before unblinding due to violations of Good Clinical Practice
guidelines at two sites, making the data unreliable. Mean follow-up (of
up to 12 months) was 358.16 61.3 days (range, 7.0–543.0).
The patients’ baseline characteristics were generally well matched
between groups (Table 1). Mean age was 67.06 10.2 years and 68.8%
were men; 96.2% of patients were in NYHA class III; mean LV ejection
Figure 1 SonRtip lead.
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..fraction was 29.56 8.3%; mean QRS width was 160.56 22.7 ms, and
85.5% had LBBB. Most patients were on beta-blockers (90.3%) and on
angiotensin-converting enzyme inhibitors or angiotensin II receptor
blockers (89.5%). Medications at baseline are summarized in the
Supplementary material online, Table S1. Successful implantation of
the SonRtip lead was achieved in 1027/1029 (99.8%) patients (one pa-
tient experienced a complication during the procedure and in the se-
cond patient, an acceptable position could not be reached).
Outcomes
Responder rates were 75.0% in the SonR arm and 70.4% in the Echo
arm (mean difference, 4.6%; 95% CI, –1.4% to 10.6%; P< 0.001 for
non-inferiority margin 10.0%) (Table 2). As the lower bound of the
confidence interval did not exceed 0%, superiority was not demon-
strated. The primary endpoint remained statistically significant when
adjusted for New York Heart Association class (mean difference,
4.9%; 95% CI, 1.1% to 11.0%; P< 0.001 for non-inferiority margin
10.0%), and was confirmed in the worst case sensitivity analysis
(mean difference, 4.3%; 95% CI, 1.9% to 10.4%; P< 0.001 for non-
inferiority margin 10.0%). Similar rates of death were reported be-
tween SonR and Echo arms (5.5% and 6.0%, respectively).
In the safety evaluation, the rates of freedom from acute and
chronic lead complications were 98.5% (95% CI, 97.3–99.2%;
P< 0.001) and 99.8% (95% CI, 99.1–100.0%; P< 0.001), respectively.
The complications are detailed in the Supplementary material online,
Table S2.
As the primary endpoints were met, the secondary endpoints
were tested for non-inferiority. In the SonR group, 21.0% of patients
were worsened vs. 25.2% in the Echo group (mean difference, 4.2%;
95% CI, –1.5% to 9.9%; P< 0.001 for non-inferiority margin 10%).
The rates of death or HF hospitalization were 14.2% with SonR and
17.6% with Echo (mean difference, 3.4%; 95% CI, –1.5% to 8.4%;
P< 0.001 for non-inferiority margin10%) (Table 2).
Long-term follow-up
When using all adjudicated data available in the database at the time
of the primary analysis, the overall mean follow-up was
548.26 190.3 days (range, 0.0–867.0). The composite of death or HF
hospitalization (pre-specified ancillary analysis) showed no significant
difference in freedom from event between SonR and Echo over time
(hazard ratio, 0.79; 95% CI, 0.60–1.06; log-rank P¼ 0.12, two-sided)
(Figure 3). A 35% risk reduction in HF hospitalization was associated
with SonR (hazard ratio, 0.65; 95% CI, 0.46–0.92; log-rank P¼ 0.01,
two sided) (Figure 4).
Ancillary and subgroup analyses
Left ventricular ejection fraction increased significantly from baseline
to 12 months in both arms (P< 0.001 two-sided). The mean increase
was similar between groups (10.86 12.3% in the SonR arm vs.
11.56 12.0% in the Echo arm; mean difference,0.6%; lower bound
97.5% 2.1%; P¼ 0.006 for non-inferiority margin 2.5%). Similarly,
the LV end-systolic volumes decreased significantly from baseline to
12 months in both arms (P< 0.001, two-sided), with a mean decrease
of44.16 54.3 mL in the SonR arm vs.50.26 61.0 mL in the Echo
arm (mean difference, 6.0; upper bound 97.5% CI, 14.9; P¼ 0.023 for
non-inferiority margin 15.0 mL).
The pre-specified analysis on the likelihood of an improved response
rate according to baseline characteristics showed consistency towards
Figure 2 Patient flow. GCP, Good Clinical Practice; mITT, modified intention to treat; RA, right atrial.
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benefit in SonR across most of the pre-specified subgroups
(Figure 5). Significant interactions (P< 0.15 two-sided) were
found in patients with a history of atrial fibrillation (n¼ 146), in
whom 70.2% were responders with SonR vs. 48.1% with Echo
(odds ratio, 2.6; 95% CI, 1.3–5.1), and in patients with renal
dysfunction (n¼ 227), in whom 61.9% were responders with
SonR vs. 46.3% with Echo (odds ratio, 1.9; 95% CI, 1.0–3.3).
Discussion
The RESPOND-CRT study was a multicentre, double-blind, random-
ized controlled clinical trial, which demonstrated that contractility
sensor-guided automatic optimization of CRT was safe and non-
inferior to the AV and VV Echo-guided approach. The primary effi-
cacy endpoint of non-inferiority was met with a patient responder
rate of 75.0% in the sensor arm vs. 70.4% in the Echo arm (mean dif-
ference, 4.6%; 95% CI, –1.4% to 10.6%; P< 0.001 for non-inferiority
margin 10.0%). Clinical response for most subgroups favoured the
SonR group, especially in patients with a history of atrial fibrillation or
renal dysfunction. Notably, the contractility sensor also had a favour-
able effect on long-term HF hospitalization.
An ideal optimization approach is one that is automated, where
the device can self-adjust and provides resynchronization therapy
over a spectrum of physiological states. To enable this requires a
dedicated atrial lead with an embedded sensor, which does not com-
promise the success of its implantation, pacing and sensing functions.
In this study, the rate of successful implantation was 99.8% and the
freedom from acute and chronic complications was 98.5% and
99.8%, respectively. Complications were very rare, with a 1% right
atrial lead dislodgement rate.
Effective CRT is dependent on the appropriate selection of pa-
tients, suitable placement of the LV pacing lead, and individualized
programming of the AV and VV timings for the delivery of the pacing
therapy.4 There is considerable heterogeneity within patients, based
on the presence of ventricular scar or fibrosis, extent of cardiac dila-
tation, electrical activation within the heart, along with a myriad of
anatomical variations in the location of the atrial and ventricular
leads.21,22 Such a variance between patients emphasizes the need for
a patient-centric approach to program the AV and VV timings, to
help maximize cardiac synchrony and the consequent increase in car-
diac contractility.7 The optimal AV interval is integral to enhancing re-
sponse to CRT, and a suboptimal AV interval may contribute to a
decline in cardiac output, by up to 20%.23,24 Even though tailoring the
delivery of CRT with AV and VV optimization is considered best
practice, this has neither been adopted as a part of routine clinical
care nor supported by the ESC 2013 guidelines.1 Prior reports from
world-wide surveys have suggested that less than half of implanting
physicians optimize the programming at implant, and that <10% of
clinicians continue to systematically optimize the AV and VV delays
during follow-up.25 Even though several studies have demonstrated
the value of Echo-guided optimization in reducing the number of
non-responders to CRT,5,26 clinicians do not perform this because of
the lack of precision, availability of skilled staff, resources, and logis-
tical challenges.7 This in turn has created a need for a simpler, auto-
mated approach to individualize the optimization of AV and VV
intervals within patients.
Optimization approaches using measures of electrical activity
within the heart and between the right and LV pacing leads have
been tested prospectively in other studies. The SMART-AV trial
was a study designed to compare a device-based algorithm with
Echo-guided optimization and a fixed nominal AV delay in a
randomized pattern.27 The primary endpoint in this study was LV
end-systolic volume and secondary endpoints included NYHA
class, quality of life score, and 6 min walk test at 6 month follow
up. The study concluded that neither the device-based algorithm
.................................................................................................
Table 1 Baseline characteristics
Baseline characteristics SonR
(N5670)
Echo
(N5328)
Demographic
Age, years 67.2610.2 66.6610.2
Men (%) 70.4 (472) 65.5 (215)
BMI, kg/m2 28.565.6 27.965.0
NYHA class
II 1.5 (10) 0.3 (1)
III 96.6 (647) 95.4 (313)
IV 1.9 (13) 4.3 (14)
Cardiac risk factors
Atrial fibrillation 14.8 (99) 16.5 (54)
Diabetes 37.3 (250) 41.8 (137)
Current smoker 33.0 (221) 32.3 (106)
Systemic hypertension 62.1 (416) 61.6 (202)
Renal dysfunction 22.8 (153) 24.7 (81)
Chronic obstructive pulmonary disease 13.1 (88) 13.7 (45)
Cause of heart failure
Ischaemic 45.5 (300) 42.5 (138)
Non-ischaemic 54.5 (360) 57.5 (187)
Electrocardiographic finding
QRS duration, ms 160.7623.1 160.0621.9
LBBB 84.0 (563) 88.4 (290)
Non-LBBB 16.0 (107) 11.6 (38)
Heart rate, b.p.m. 70.7613.4 70.9613.6
PR interval, ms 188.1644.9 188.3642.7
Systolic blood pressure, mmHg 125.7619.8 124.5620.2
Diastolic blood pressure, mmHg 72.7612.0 71.8611.0
Echocardiographic finding
Left ventricular ejection fraction
25% 33.6 (225) 30.5 (100)
>25% 66.4 (445) 69.5 (228)
Left ventricular end-systolic volume, mL 162.0672.5 159.8675.0
Left ventricular end-diastolic volume, mL 226.2688.0 225.6694.3
Concomitant cardiac medications
Beta-blocker 89.4 (599) 92.1 (302)
ACE inhibitor, substitutes, or ARB 89.9 (602) 88.7 (291)
Ivabradine 9.0 (60) 10.4 (34)
Diuretic 79.6 (533) 84.5 (277)
Spironolactone 57.9 (388) 56.7 (186)
There were no significant differences between groups, except for the NYHA
class distribution (P< 0.05). Values are mean6 SD or % (n).
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker, BMI,
body mass index; LBBB, left bundle branch block; NYHA, New York Heart
Association functional class.
734 J. Brugada et al.
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..(SmartDelayTM) nor Echo-guided optimization was superior to a
fixed AV delay of 120 ms. It does appear that this study was under-
powered and the definition of a responder may have been too
stringent. Also, the optimization method in the SMART-AV study
used a static variable that was manually programmed into the de-
vice at a clinic visits.27 Like the Echo-guided approach, this algo-
rithm is limited by its inability to adapt to exercise and progressive
remodelling of the heart.
The Adaptive CRT (aCRTTM) study recently examined an algo-
rithm enabling RV-synchronized LV and bi-ventricular pacing, in the
setting of intact intrinsic AV conduction.28 This report demonstrated
non-inferiority of the algorithm on the overall population when com-
pared with Echo-guided optimization at 6 months of follow-up.28
aCRT seems to benefit to patients with normal AV interval at base-
line while being potentially suboptimal for patients with prolonged
AV.29 Unlike any of the above optimization strategies, the signal
................................................
....................................................................................................................................................................................................................
Table 2 Clinical outcomes
Outcome SonR (N5649) Echo (N5318) Mean % difference
(95% CI)
P-value
% (n) Non-inferiority Superiority
Clinical respondersa 75.0 (487) 70.4 (224) 4.6 (1.4, 10.6) <0.001 0.13
NYHA improved 65.6 (426) 61.9 (197)
Stable NYHA, improved quality of life 9.4 (61) 8.5 (27)
Clinical non-respondersb 25.0 (162) 29.6 (94)
Clinically stable 4.0 (26) 4.4 (14)
Clinically worsened: secondary endpoint 21.0 (136) 25.2 (80) 4.2 (1.5, 9.9) <0.001 0.15
Death from any cause 5.5 (36) 6.0 (19)
If no death, HF-related event 10.2 (66) 12.9 (41)
Worsened NYHA class 0.9 (6) 0.3 (1)
Worsened quality of life; stable NYHA stable 4.3 (28) 6.0 (19)
Death or HF hospitalization 14.2 (92) 17.6 (56) 3.4 (1.5, 8.4) <0.001 0.18
P-value for non-inferiority is based on one-sided Z-test of two binomial proportions at 0.025 alpha level with 10.0% non-inferiority margin; P-value for superiority is based on
two-sided Z-test.
CI, confidence interval; HF, heart failure; NYHA, New York Heart Association functional class.
aPatients who are clinically improved according to the primary efficacy endpoint.
bPatients who are either stable or deteriorated according to the primary efficacy endpoint.
Figure 3 Freedom from all-cause mortality or heart failure hospitalization. CI, confidence interval; HR, hazard ratio.
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recorded by the SonR sensor reflects global ventricular contractility.
Previous work has suggested that the signal recorded on the atrial
lead is stable and reproducible during atrial fibrillation, exercise, and
sensitive to pacing conditions.30
Of note, the clinical characteristics of patients in RESPOND-
CRT were comparable to those in other studies.2,3 Majority of the
patients were NYHA class III, with an even distribution of ischae-
mic and non-ischaemic cardiomyopathy. Notably current practice
in CRT implantations includes a substantial percentage of NYHA
class II patients (30–50%), as opposed to the population of the
RESPOND CRT trial. Also noteworthy, the percentage of LBBB
patients was higher in the RESPOND-CRT trial as compared with
historical trials on HF patients, most likely due to the evolution of
the guidelines. Defining response to CRT is complex and there re-
mains a high degree of variance between responder rates, when
one examines functional endpoints vs. that of anatomical re-
modelling.31 We used a composite of functional as well as hard
endpoints, inclusive of HF and all-cause mortality in defining re-
sponders. Heart failure hospitalization was a pre-specified end-
point and examined separately. Notably, the overall response in
the SonR arm was higher (75%) than that reported in the Echo arm
(70.4%), as well in historical controls from other previous studies
that used optimization. The SonR arm was observed to have
reduced HF hospitalization rate. This could potentially have cost
implications, as HF hospitalization is a major component of the
overall cost related to the management of this cohort of patients.
Importantly the sensor-strategy was notably better in patients
with a past history of atrial fibrillation and renal dysfunction. We
could speculate that this subgroup of patients is sicker and haemody-
namically more tenuous, and therefore benefit from more frequent
CRT optimization. The ability of the sensor strategy to frequently op-
timize and adjust for exercise periods may result in benefit in these
sicker patients, especially during the augmented stress of exercise
and over the course of remodelling. In this study, the trend to benefit
from continuous optimization emerged early in the course with a re-
duction of HF hospitalization that continued to improve over the ex-
tended follow-up period.
Of the 1039 patients recruited 19 patients from two sites were
excluded from the analysis prior to unblinding. This decision was
made due to violations of good clinical practice from that centre.
Also, a larger proportion of patients in this study were NYHA class
III, and generalizing the results of this study beyond this subgroup of
patients must be done cautiously. The Echo-guided arm did not re-
peatedly undergo optimization. This cohort of patients had their ini-
tial programming performed soon after the implant, which was then
repeated based on clinical grounds and physician discretion. This is
congruent with current clinical practice guidelines for CRT.
In summary, RESPOND-CRT is the first double-blind randomized
controlled clinical trial examining the efficacy and safety of a contractil-
ity sensor-guided CRT optimization approach. This non-inferiority
study met its primary endpoints of safety and efficacy. Clinical response
for most subgroups was in favour of the automatic optimization arm
using the SonR sensor, especially in patients with a prior history of atrial
fibrillation or renal dysfunction. Notably, the contractility sensor ap-
proach was also associated with a reduction in HF hospitalization.
Supplementary material
Supplementary material is available at European Heart Journal online.
Figure 4 Freedom from heart failure hospitalization. CI, confidence interval; HR, hazard ratio.
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